期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

miR-143在结直肠癌中表达及意义 被引量：2

Expression of miR-143 in colorectal cancer and its significance
原文传递
导出
摘要 目的探讨miR-143在结直肠癌中的表达情况及其与临床病理指标间关系。方法采用RT-PCR法检测miR-143在17例结肠癌患者的肿瘤标本(结肠癌组)及癌旁黏膜组织(结肠黏膜组)和81例直肠癌患者的肿瘤标本(直肠癌组)及癌旁黏膜组织(直肠黏膜组)标本中的表达情况,并分析其与结直肠癌患者临床病理指标间关系。结果结肠癌组miR-143表达水平(Ct值为15.96±1.76)明显低于结肠黏膜组(Ct值为14.34±3.44),差异有统计学意义(P=0.023),直肠癌组miR-143表达水平(Ct值为14.66±3.18)与直肠黏膜组(Ct值为14.29±4.82)比较,差异无统计学意义(P=0.351);直肠癌组miR-145表达下调在性别、年龄、TNM分期、脉管浸润上差异无统计学意义(P>0.05)。结论 miR-143仅在结肠癌中表达降低,在直肠癌中表达无变化,miR-143仅参与了结肠癌的发生,结肠癌和直肠癌可能有不同的癌变分子基础。 Objective To investigate the expression of miR-143 and analyze its relationship with clinicopathological variables in colorectal cancer patients.Methods Real-time PCR was used to detect the expression of miR-143 in 17 cases of colon cancer and 81 cases of rectal cancer and the corresponding normal mucosa tissue.The relationship of the expression of miR-143 with clinicopathological variables including sex,age,TNM stage and vessel invasion was analyzed.Results The expression of miR-143 was lower in colon cancer tissue（Ct：15.96±1.76） than that in colon mucosa tissue（Ct：14.34±3.44）（P=0.023）,and there was no significant difference between rectal cancer tissue（Ct：14.66±3.18） and rectal mucosa tissue（Ct：14.29±4.82）（P=0.351）.There was no significant difference in miR-143 expression in different sexes,ages,TNM stages and vessel invasion（P0.05）.Conclusion The expression of miR-143 is low in colon cancer tissue and does not differ in rectal cancer tissue,and is involved in the development of colon cancer.Colon cancer may have the different etiology from rectal cancer.
作者 王朝杰 温一阳 周云
机构地区 郑州大学人民医院 河南省人民医院肿瘤科
出处 《中华实用诊断与治疗杂志》 2013年第7期668-669,672,共3页 Journal of Chinese Practical Diagnosis and Therapy
关键词 结肠癌 直肠癌 MIR-143 Colon cancer rectal cancer miR-145
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Michael M Z, 0 Connor S M, van Holst Pcllekaan , et al , Reduced accumulation of specific microfc N.As in colorcctal ncoplasia[J], Mol Cancer Res, 2003,1 (12) ,882,891,.
  • 2Akao Y, Nakagawa y, Naoe T, MicroRNAs],13 and 1,15 are possible common onco-microRAs in human c(tnccrs[J]. Onco Rep,2006,16(4) ,815-850,.
  • 3Nakajima G, Hayashi K, Xi Y, PI al . Non-coding microRNAs hsa-lct-7g and hsa-mi R-f S b arc associated with chcmorcsponsc to S-l in colon cancerj]], Cancer Gcnomics Proteomics , 2006, i (j),:1l7-:l24. (rtt 672 gf).
  • 4聂宇,张洋,韩变梅,王恺隽,丛祥凤,陈曦.常规TRIzol法提取血清microRNA的改良[J].中华实用诊断与治疗杂志,2011,25(5):427-428. 被引量：13
  • 5何仁豪,史晨辉.骨性关节炎发病机制及与microRNA相关性研究进展[J].中华实用诊断与治疗杂志,2012,26(11):1045-1047. 被引量：18
  • 6Slaby O, Svoboda M, Fabian P, et al , Altered expression of l1l21. milc-S , miR-113 and rniR-145 is related to rli ric-opnt holop ic features of colorectal cancer[J] Oncology, 20117) : 397 402.
  • 7Cmnmins J M, Fie Y, Leary R J, et al. The colorectal microlNAomc[J]. Proc Natl Acad Sci LISA, 2006, 103 (10) :3687 3692.
  • 8Kulda V, Pesta M, Topolcan O, PI al. RdevanC of Illil .m miR-143 expression in tissue sample of col orcc t al carcinoma .urd its liver metastasesU OJ. Cancer Genet Cyrogener . 2010, 200 ( 154-160.
  • 9Chang K H, Miller N, Kheirelseid E A, d a.l , MinoRJA signat ure analysis in colorcctal cancer: idcn t i fica t ion ol expression profiles in stage n tumors n s soci at cd wit h aggrvsdiseasc[J]. Int] ColorcctaIDis,2011,26(11):H1122.

二级参考文献23

  • 1胥少汀,葛宝丰,徐印坎.实用骨科学[M].3版.北京:人民军医出版社,2006:996
  • 2Fuku I N, Zhu Y, Maloney W J. Stimulation of BMP-2 expression by pro-inflammatory cytokincs IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes[J]. J Bone Joint Surg Am,2003,85(Supp13) :59-66.
  • 3Blaney Davidson E N, Scharstuhl A, Vitters E L, et al.Reduced transforming growth factor-beta signaling in cartilage of old mice: role in impaired repair capacity[J]. Arthritis Res Ther,2005,7(6) :R1338-1347.
  • 4Flannery C R, Little C B, Caterson B, et al. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases ( MMPs ) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes [J ]. Matrix Biol, 1999, 18 ( 3 ) 225-237.
  • 5Freemont A J, Byers R J, Taiwo Y O, et al. In situ zymographic localisation of type Ⅱ collagen degrading activity in osteoarthritic human articular cartilage[J]. Ann Rheum Dis, 2004,58(6) : 356-357.
  • 6Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data[J]. Nacleic Acids Res, 2011,39(Datebase issue) :D152-D157.
  • 7Lee Y, Ahn C, Han J, et al. The nuclear RNase Ⅲ Drosha initiates rnieroRNA processing[J]. Nature, 2003,425 (6956) : 415-419.
  • 8Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Ce11,2004,116(2),281-297.
  • 9John B, Enright A J, Aravin A, et al. Human microRNA targets[J]. PLoS Biol,2004,2(11) :e363.
  • 10Kobayashi T, Lu J, Cobb B S, et al. Dicer-dependent pathways regulate ehondrocyte proliferation and differentiation [J]. Proc Natl Acad Sei USA,2008,105(6):1949-1954.

共引文献29

同被引文献22

  • 1Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs [J]. Science,2001,294(5543) :853-858.
  • 2Fuse M, Kojima S, Enokida H, et al. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer[J]. J Hum Genet,2012,57(11) :691-699.
  • 3Xu R S, Wu X D, Zhang S Q, etal. The tumor suppressor gene RhoBTB1 is a novel target of miR-31 in human colon cancer[J]. Int J Oncol,2013,42(2) :676-682.
  • 4Cottonham C L, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells[J]. J Biol Chem,2010,285(46) :35293-35302.
  • 5Creighton C J, Fountain M D, Yu Z, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers[J]. Cancer Res,2010,70(5) :1906-1915.
  • 6Yamagishi M, Nakano K, Miyake A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers[J]. Cancer Cell, 2012,21 (1) :121-135.
  • 7Pedrioli D M, Karpanen T, Dabouras V, et al. miR-31 functions as a negative regulator of lymphatic vascular lineage- specific differentiation in vitro and vascular development in vivo [J]. Mol Cell Biol,2010,30(14) :3620-3634.
  • 8Xue F, Li H, Zhang J, et al. miR 31 regulates interleukin-2 and kinase suppressor of ras 2 during T cell activation[J]. Genes Immun, 2013,14(2) : 127-131.
  • 9Korner C, Keklikoglou I, Bender C, et al. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon)[J]. J Biol Chem,2013, 288(12) :8750-8761.
  • 10Valastyan S, Chang A, Benaich N, etal. Activation of miR-31 function in already established metastases elicits metastatic regression[J]. Genes Dev,2011,25(6) :646-659.

引证文献2

二级引证文献10

中华实用诊断与治疗杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部